Discover 1,406 paid clinical trials in St. Louis, Missouri. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
St. Louis currently offers medical research opportunities for a variety of conditions, including cancer, heart disease, prurigo nodularis, and pain management. The city's leading institutions are actively recruiting participants, offering opportunities for healthy volunteers in paid studies, as well as those seeking trials for specific health conditions, providing access to innovative treatments and advanced medical care.
Filter
2
Filter results
Results: 1,406
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
for
Steroid Refractory GVHD
Location: St Louis MO, Cincinnati OH, Columbus OH, Atlanta GA,
Sponsor: ReAlta Life Sciences, Inc.
Sex: All
Age: 12+
Code: NCT06343792
Phase 2, Recruiting
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
for
Hypertriglyceridemia
Location: St Louis MO, Springfield IL, Memphis TN,
Sponsor: Marea Therapeutics
Sex: All
Age: 18 - 70+
Code: NCT07028749
Phase 2, Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
for
Dystonia
Location: St Louis MO, Overland Park KS, Memphis TN, Nashville TN,
Sponsor: Vima Therapeutics
Sex: All
Age: 18 - 70
Code: NCT07304089
Phase 2, Recruiting
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
for
Hidradenitis Suppurativa (HS)
Location: St Louis MO, Plainfield IN, Chicago IL, Smyrna TN,
Sponsor: Oruka Therapeutics, Inc.
Sex: All
Age: 18 - 70+
Code: NCT07783542
Phase 2, Recruiting
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
for
Higher-risk Myelodysplastic Syndrome
Location: St Louis MO, Indianapolis IN, Louisville KY, Chicago IL,
Sponsor: Ascentage Pharma Group Inc.
Sex: All
Age: 18+
Code: NCT06641414
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Location: St Louis MO, Nashville TN, Philadelphia PA,
Sponsor: MOMA Therapeutics
Sex: All
Age: 18+
Code: NCT06545942
Phase 1, Recruiting
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
for
Non-obstructive Hypertrophic Cardiomyopathy
Location: St Louis MO, Chicago IL, Grand Rapids MI, Rochester MN,
Sponsor: Imbria Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT07023614
Phase 2, Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
for
Bladder (Urothelial, Transitional Cell) Cancer,
Location: St Louis MO, Little Rock AR, Atlanta GA, Arlington TX,
Sponsor: Protara Therapeutics
Sex: All
Age: 18+
Code: NCT07480356
Phase 3, Recruiting
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
for
Graves Disease
Location: St Louis MO, Springfield IL, Champaign IL,
Sponsor: Biohaven Therapeutics Ltd.
Sex: All
Age: 18 - 70
Code: NCT07661056
Phase 3, Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
for
Graves' Disease
Location: St Louis MO, Jefferson City MO, Kansas City MO,
Sponsor: Immunovant Sciences GmbH
Sex: All
Age: 18 - 70+
Code: NCT07018323
Phase 2, Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
for
Atrial Fibrillation (AF)
Location: St Louis MO, Evansville IN, Memphis TN, Kansas City MO,
Sponsor: Anthos Therapeutics, Inc.
Sex: All
Age: 65+
Code: NCT05712200
Phase 3, Recruiting
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations